Rathindra N. Bose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rathindra N. Bose has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Chrys Wesdemiotis
Department of Chemistry, University of Akron , Akron, Ohio 44325, USA
1 shared publicationDiane Stroup
Department of Chemistry, Kent State University , Kent, OH 44242, USA
1 shared publicationL. Maurmann
Department of Chemistry, Kansas State University, Manhattan, KS, 66506, USA
1 shared publicationLamis Judah
Department of Chemistry, University of Houston , Houston, TX 77204, USA
1 shared publication- Louiza Belkacemi
University of Houston, Departments of Biology and Biochemistry, Houston, TX, 77204, USA
1 shared publication N. R. Adams
Baylor College of Medicine
1 shared publication
Latest Publications
- 7 April 2015
- Published by Springer Nature in Apoptosis
- Vol. 20 (7) , 960-974
A novel cisplatin mediated apoptosis pathway is associated with acid sphingomyelinase and FAS proapoptotic protein activation in ovarian cancer
Platinum-based anticancer drugs, including cisplatin and carboplatin, have been cornerstones in the treatment of solid tumors. We report here that these DNA-damaging agents, particularly cisplatin, induce apoptosis through plasma membrane disruption, triggering FAS death receptor via mitochondrial (intrinsic) pathways. Our objectives were to: quantify the composition of membrane metabolites; and determine the potential involvement of acid sphingomyelinase (ASMase) in the FAS-mediated apoptosis in ovarian cancer after cisplatin treatment. The resulting analysis revealed enhanced apoptosis as measured by: increased phosphocholine, and glycerophosphocholine; elevated cellular energetics; and phosphocreatine and nucleoside triphosphate concentrations. The plasma membrane alterations were accompanied by increased ASMase activity, leading to the upregulation of FAS, FASL and related pro-apoptotic BAX and PUMA genes. Moreover FAS, FASL, BAX, PUMA, CASPASE-3 and -9 proteins were upregulated. Our findings implicate ASMase activity and the intrinsic pathways in cisplatin-mediated membrane demise, and contribute to our understanding of the mechanisms by which ovarian tumors may become resistant to cisplatin.
- 7 April 2015
- Published by Springer Nature in Apoptosis
- Vol. 20 (7) , 960-974
A novel cisplatin mediated apoptosis pathway is associated with acid sphingomyelinase and FAS proapoptotic protein activation in ovarian cancer
Platinum-based anticancer drugs, including cisplatin and carboplatin, have been cornerstones in the treatment of solid tumors. We report here that these DNA-damaging agents, particularly cisplatin, induce apoptosis through plasma membrane disruption, triggering FAS death receptor via mitochondrial (intrinsic) pathways. Our objectives were to: quantify the composition of membrane metabolites; and determine the potential involvement of acid sphingomyelinase (ASMase) in the FAS-mediated apoptosis in ovarian cancer after cisplatin treatment. The resulting analysis revealed enhanced apoptosis as measured by: increased phosphocholine, and glycerophosphocholine; elevated cellular energetics; and phosphocreatine and nucleoside triphosphate concentrations. The plasma membrane alterations were accompanied by increased ASMase activity, leading to the upregulation of FAS, FASL and related pro-apoptotic BAX and PUMA genes. Moreover FAS, FASL, BAX, PUMA, CASPASE-3 and -9 proteins were upregulated. Our findings implicate ASMase activity and the intrinsic pathways in cisplatin-mediated membrane demise, and contribute to our understanding of the mechanisms by which ovarian tumors may become resistant to cisplatin.
- Open Access
- 1 January 2014
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 3 (1) , 56-66
DNA damage by oxo- and peroxo-chromium(v) complexes: insight into the mutation and carcinogenesis mechanisms
The carcinogenic and mutagenic properties of chromium(vi) compounds are attributed to hypervalent chromium species, especially metastable oxo- and per
- 1 January 2014
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 3 (1) , 56-66
Open AccessDNA damage by oxo- and peroxo-chromium(v) complexes: insight into the mutation and carcinogenesis mechanisms
The carcinogenic and mutagenic properties of chromium(vi) compounds are attributed to hypervalent chromium species, especially metastable oxo- and per